tamoxifen


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to tamoxifen: Nolvadex, Tamoxifen citrate

ta·mox·i·fen

 (tə-mŏk′sə-fĕn)
n.
A drug that is a selective estrogen receptor modulator, C26H29NOS, used in the form of its citrate primarily to treat breast cancer in women whose tumors are estrogen-dependent and to prevent breast cancer in high-risk women.

[t(rans)- + am(ino)- + alteration of oxy- + alteration of phen(ol).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

tamoxifen

(təˈmɒksɪfɛn)
n
(Pathology) a drug that antagonizes the action of oestrogen and is used to treat breast cancer and some types of infertility in women
[C20: altered from t(rans-) + am(ine) + oxy-2 + phen(ol)]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

ta•mox•i•fen

(təˈmɒk sə fən, -ˌfɛn)

n.
a drug, C26H29NO, that blocks the estrogen receptors on cancer cells, used to treat breast cancer and to prevent recurrence or occurrence of breast cancer in high-risk people.
[1970–75; perhaps t (rans)- + am (ino)- + oxy-2 + phen (yl), with resp. of y and ph]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.tamoxifen - an antagonist for estrogen that is used in the treatment of breast cancer
antagonist - a drug that neutralizes or counteracts the effects of another drug
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

tamoxifen

n tamoxifeno
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Dare Bioscience announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, an international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology.
TUESDAY, June 5, 2018 (HealthDay News) -- The addition of ovarian suppression to tamoxifen is associated with increased survival versus tamoxifen alone among premenopausal women with breast cancer, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.
Tamoxifen is a selective estrogen receptor modulator (SERM), which is widely used as hormone therapy for estrogen-receptor-positive breast cancer.
6, 2016) suggests that tamoxifen (Novaldex[R]), and medications from another class of drugs (aromatase inhibitors) may reduce this risk.
In women diagnosed with breast cancer, taking tamoxifen and/or aromatase inhibitors reduces the risk of developing cancer in their other breast, according to a study published online Oct.
Valley Cottage, NY, January 01, 2016 --(PR.com)-- Tamoxifen is an antagonist of the estrogen receptor in breast tissue.
SAN DIEGO -- Researchers at the University of California, San Diego, School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments.
SAN ANTONIO -- Adding ovarian suppression to 5 years of tamoxifen in women with hormone receptor-positive early breast cancer who remain premenopausal following chemotherapy provides a markedly greater reduction in breast cancer recurrence, compared with standard adjuvant therapy with tamoxifen alone--and combining ovarian suppression with an aromatase inhibitor instead of tamoxifen further improves outcomes, Dr.
Tamoxifen (trade name Nolvadex) has been hailed as a 'wonder drug' by many physicians (and patients) since it's inception in the 1970's.
In most tamoxifen research, the studies have lasted for a period of five years, although some benefits continue in years 5 to 10.
Women who have hormone-sensitive breast cancer and who have taken tamoxifen for 5 years as adjuvant therapy stand to benefit from an additional 5 years of the drug, according to preliminary findings from the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial.